SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Torrent Pharma gains on reporting 8% rise in Q3 consolidated net profit

24 Jan 2012 Evaluate

Torrent Pharmaceuticals is currently trading at Rs 556.00, up by 7.85 points or 1.43% from its previous closing of Rs 548.15 on the BSE.

The scrip opened at Rs 540.00 and has touched a high and low of Rs 563.30 and Rs 540.00 respectively. So far 313 shares were traded on the counter.

The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 686.95 on 21-Jul-2011 and a 52 week low of Rs 499.00 on 28-Apr-2011.

Last one week high and low of the scrip stood at Rs 579.00 and Rs 536.65 respectively. The current market cap of the company is Rs 4704.39 crore.

The promoters holding in the company stood at 71.51% while Institutions and Non-Institutions held 17.16% and 11.34% respectively.

Torrent Pharmaceuticals posted a 6.73% fall in net profit after tax of Rs 61.51 crore for the quarter ended December 31, 2011 as compared to Rs 65.95 crore for the same quarter in the previous year. Total income has increased by 13.96% from Rs 461.37 crore for Q3FY11 to Rs 525.78 crore in the quarter under review.

On the consolidated basis the group has posted a net profit rise of 8.15% to Rs 83.18 crore for the quarter ended December 31, 2011 as compared to Rs 76.91 crore in the same quarter last year. Total Income of the company improved by 20.64% to Rs 698.93 crore for the quarter compared to Rs 579.35 crore in the quarter, year ago.

Torrent Pharma Share Price

4660.15 142.00 (3.14%)
29-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1872.60
Dr. Reddys Labs. 1376.30
Cipla 1453.50
Zydus Lifesciences 1121.65
Lupin 2407.45
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: